UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 1 ...

Nephros, Inc. (NASDAQ:NEPH) Q3 2020 Results Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Group, IR Andy Astor - Chief Executive Officer Dan D'Agostino - Chief Financial Officer Conference Call Participants Howard Halpern - Taglich Brothers Jeremy Pearlman - Maxim Group Operator Good afternoon. And welcome to the Nephros Third Quarter 2020 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today???s p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other jurisdiction of incorporation or organization) 380 Lackawanna Place South Orange, NJ 07079 (Address of principal executive offices) (Zip Code) (201) 343-5202 For the quarterly period ended: September 30, 2020 OR [ ] TRANSITION REPORT PUR ...

Nephros, Inc. (NASDAQ:NEPH) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Kirin Smith - Investor Relations Daron Evans - President & Chief Executive Officer Andy Astor - Chief Operating Officer & Chief Financial Officer Conference Call Participants Howard Halpern - Taglich Brothers Anthony Vendetti - Maxim Group Wayne Cadwallader - Elkhorn Partners Operator Good afternoon, and welcome to the Nephros, Inc. Second Quarter 2020 Financial Results Conference Call. All participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or ot ...

Nephros, Inc. (NASDAQ:NEPH) Q1 2020 Results Conference Call May 6, 2020 4:30 PM ET Company Participants Kirin Smith - Investor Relations Daron Evans - President and Chief Executive Officer Andrew Astor - Chief Operating Officer and Chief Financial Officer Conference Call Participants Howard Halpern - Taglich Brothers Anthony Vendetti - Maxim Group Bob Wassermann - Benchmark Operator Good day and welcome to the Nephros First Quarter Financial Results Conference Call. Today's conference is being recorded. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

Nephros, Inc. (NASDAQ:NEPH) Q4 2019 Results Conference Call February 27, 2020 4:30 PM ET Company Participants Kirin Smith - Investor Relations Daron Evans - President and Chief Executive Officer Andrew Astor - Chief Operating Officer and Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Howard Halpern - Taglich Brothers Michael Brick - National Securities Bob Wassermann - Benchmark Company Art Winston - Pilot Advisors Operator Good day, and welcome to the Nephros Incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3971809 (State ...